検索結果

期 間 中心窩下脈絡膜新生 血管を伴う加齢黄斑 変性：8 年（2020 年 3 月 25 日～2028 年 3 月 24 日） 糖尿病黄斑浮腫：中 心窩下脈絡膜新生血 管を伴う加齢黄斑変 性の再審査期間の残 余期間 増殖糖尿病網膜症： 中心窩下脈絡膜新生 血管を伴う加齢黄斑 変性の再審査期間の 残余期間 承 認 番 号 30200AMX00429000 国 際 誕 生 日 2019 年 10 月...

·····························································································34 2．有効期間··································································································...

品安全性監視活動 通常の医薬品安全性監視活動の概要： 副作用、 文献・学会情報及び外国措置報告等の収集・確認・分析に基づく安全対策の検討 （及 び実行） 追加の医薬品安全性監視活動 市販直後調査 実施期間：販売開始から 6 ヵ月間 評価、報告の予定時期：調査終了から 2 ヵ月以内 特定使用成績調査（長期投与） 【安全性検討事項】 温度覚の異常 【目的】 本剤とドライアイ治療剤を含む他剤との長期併用...

·····························································································30 2．有効期間··································································································...

·····························································································30 2．有効期間··································································································...